• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Stryker plans $2B share buyback

Stryker plans $2B share buyback

March 3, 2015 By Brad Perriello

Stryker plans $2B share buyback

Stryker (NYSE:SYK) said today that its board of directors authorized a share repurchasing program worth up to $2 billion.

Kalamazoo, Mich.-based Stryker said it still has $583 million in stock buybacks authorized under a prior share buyback.

Companies often initiate share repurchases to boost the price of their stock.

"We remain committed to pursuing a capital allocation strategy that includes acquisitions, dividends and share repurchases," chairman & CEO Kevin Lobo said in prepared remarks. "While M&A activity across the breadth of our product and service offerings will remain the primary focus of our long-term growth strategy, this new authorization recognizes that the strength of our balance sheet is sufficient to enable more significant share repurchases. We believe that efficiently deploying our balance sheet will enable growth in sales and earnings and maximize shareholder returns."

Leerink Partners analyst Richard Newitter said the repurchase doesn’t necessarily take Stryker off the M&A board, but wrote that the move might make a long-rumored tie-up with rival Smith & Nephew (NYSE:SNN) less likely.

"This is modestly bigger than the company’s last few share repurchase programs, but not so big in our view that it takes additional M&A off the table," Newitter wrote this morning in a note to investors. "SYK’s balance sheet has been very much in focus as it represents a key avenue to shareholder value creation, in our view, for the company. M&A has historically been the first priority, followed by share repos and then dividends. While this buyback announcement is larger than prior authorizations, we don’t think it takes M&A off the table by any stretch. However, at the margin it could be viewed as a sign that larger M&A (i.e., a much-speculated potential bid for SNN) – at least over the nearer term – is less likely. In all, we view SYK’s balance sheet flexibility favorably, and we view buybacks as one of a number of cash deployment mechanisms at the company’s disposal to drive higher shareholder value."

Leerink has Stryker’s stock rated at "outperform." SYK shares were trading at $94.25 apiece in mid-day activity today, down 1.9%.

Filed Under: News Well, Orthopedics, Wall Street Beat Tagged With: Stryker

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy